石四药重磅降压药过评,成功切入超20家药企混战的心血管赛道,新品放量可期

摩熵医药大数据
Oct 22, 2025

近日,石四药集团发布公告,公司以仿制4类报产的苯磺酸左氨氯地平片获批并视同过评。摩熵医药数据显示,截至目前,该品种有超20家药企获批并过评。截图来源:企业官网苯磺酸左氨氯地平片是一种钙通道阻滞剂,通过选择性抑制血管平滑肌细胞膜上的钙离子内流,降低外周血管阻力,从而发挥降压和缓解心绞痛的作用。据摩熵医药数据库显示,苯磺酸左氨氯地平片在2024年全终端医院市场的销售额超20亿元,是全终端医院心血管系统...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10